Exane Derivatives’s PepsiCo PEP Stock Holding History

Exane Derivatives’s Portfolio PEP Stock Details PEP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-700	Closed	-$20.3K	–	703
2019 Q3	$20.3K	Hold	700	–	–	﹤0.01%	398
2019 Q2	$57K	Buy	+700	New	+$89.7K	0.01%	380

Other funds holding PEP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Exane Derivatives's PEP Position: Q2 2022 in Review

Exane Derivatives reduced its PepsiCo (PEP) stake by 2.1% in Q2 2022, selling an estimated $13.6K and leaving 3,723 shares worth $620K. The position accounts for 0.36% of the portfolio, ranked #62.

Exane Derivatives first reported a position in PEP in Q4 2014 and has held it in 26 quarters since. The position peaked at $26.2M in Q2 2019. 3,012 funds tracked by Wall St. Rank hold PEP as of Q2 2022.

Exane Derivatives held 3,723 shares of PepsiCo worth $620K as of Q2 2022.
Exane Derivatives sold 81 PepsiCo shares in Q2 2022, an estimated $13.6K.
PepsiCo made up 0.36% of Exane Derivatives's portfolio in Q2 2022, its #62 holding.
Exane Derivatives first reported a position in PepsiCo in Q4 2014 and has held it in 26 quarters since.
Exane Derivatives's PepsiCo position peaked at $26.2M in Q2 2019.
3,012 funds tracked by Wall St. Rank held PepsiCo as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.